Effect of high-dose intravenous immunoglobulin treatment in therapy-resistant chronic spontaneous urticaria
H Mitzel-Kaoukhov, P Staubach… - Annals of Allergy, Asthma …, 2010 - Elsevier
BACKGROUND: Chronic spontaneous urticaria (CSU) lasting more than 6 weeks is one of
the most disabling types of urticaria and often results in severely impaired quality of life.
Patients with CSU are often unsatisfied with the standard treatment. Another treatment
option recommended for patients with so-called nonresponding CSU according to the
newest guidelines is intravenous immunoglobulin (IVIG). OBJECTIVE: To assess the efficacy
and safety of high-dose IVIG as a treatment option in patients with therapy-resistant CSU …
the most disabling types of urticaria and often results in severely impaired quality of life.
Patients with CSU are often unsatisfied with the standard treatment. Another treatment
option recommended for patients with so-called nonresponding CSU according to the
newest guidelines is intravenous immunoglobulin (IVIG). OBJECTIVE: To assess the efficacy
and safety of high-dose IVIG as a treatment option in patients with therapy-resistant CSU …